Literature DB >> 14689075

[Tuberculosis-current therapeutic principles].

U Greinert1, P Zabel.   

Abstract

Chemotherapy for tuberculosis is indicated in case of disease as well as in latent tuberculosis infection. Standard medication for drug-susceptible tuberculosis consists of isoniazid and rifampicin for six months with additional pyrazinamide and ethambutol for the first two months. Prolonged treatment is necessary in cases of cavernous pulmonary tuberculosis with lack of negative cultures by two months of therapy, in tuberculosis of the central nervous system and in some cases of superficial lymph node disease. Especially in multiple-drug resistant tuberculosis prolonged treatment with three or more drugs, that have been proven to be effective by susceptability testing, is mandatory. Attention must be payed to reliable delivery of chemotherapy as well as to side effects of antituberculosis medications. The classical treatment for latent tuberculosis infection is isoniazid. Multidrug short-course therapy, which has been shown to be equally effective, enhances patients' compliance, but toxicity is increased.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14689075     DOI: 10.1007/s00108-003-1038-x

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  26 in total

1.  American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis.

Authors:  Henry M Blumberg; William J Burman; Richard E Chaisson; Charles L Daley; Sue C Etkind; Lloyd N Friedman; Paula Fujiwara; Malgosia Grzemska; Philip C Hopewell; Michael D Iseman; Robert M Jasmer; Venkatarama Koppaka; Richard I Menzies; Richard J O'Brien; Randall R Reves; Lee B Reichman; Patricia M Simone; Jeffrey R Starke; Andrew A Vernon
Journal:  Am J Respir Crit Care Med       Date:  2003-02-15       Impact factor: 21.405

2.  Image-guided percutaneous drainage of tuberculous iliopsoas and spondylodiskitic abscesses: midterm results.

Authors:  Hasan Dinç; Ali Ahmetoğlu; Süleyman Baykal; Ahmet Sari; Ozgür Sayil; Halit Reşit Gümele
Journal:  Radiology       Date:  2002-11       Impact factor: 11.105

3.  Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy.

Authors:  Gillian L Dean; Simon G Edwards; Natalie J Ives; Gail Matthews; Emma F Fox; Lesley Navaratne; Martin Fisher; Graham P Taylor; Rob Miller; Chris B Taylor; Annemiek de Ruiter; Anton L Pozniak
Journal:  AIDS       Date:  2002-01-04       Impact factor: 4.177

Review 4.  Therapeutic drug monitoring in the treatment of tuberculosis.

Authors:  Charles A Peloquin
Journal:  Drugs       Date:  2002       Impact factor: 9.546

5.  Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial.

Authors:  Robert M Jasmer; Jussi J Saukkonen; Henry M Blumberg; Charles L Daley; John Bernardo; Eric Vittinghoff; Mark D King; L Masae Kawamura; Philip C Hopewell
Journal:  Ann Intern Med       Date:  2002-10-15       Impact factor: 25.391

6.  Lumbar and lumbosacral tuberculous spondylodiscitis in adults. Redefining the indications for surgery.

Authors:  S Bhojraj; A Nene
Journal:  J Bone Joint Surg Br       Date:  2002-05

7.  Guidelines for preventing opportunistic infections among HIV-infected persons--2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America.

Authors:  Henry Masur; Jonathan E Kaplan; King K Holmes
Journal:  Ann Intern Med       Date:  2002-09-03       Impact factor: 25.391

8.  Extrapulmonary tuberculosis in patients with human immunodeficiency virus infection.

Authors:  R W Shafer; D S Kim; J P Weiss; J M Quale
Journal:  Medicine (Baltimore)       Date:  1991-11       Impact factor: 1.889

9.  The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis.

Authors:  S E Weis; P C Slocum; F X Blais; B King; M Nunn; G B Matney; E Gomez; B H Foresman
Journal:  N Engl J Med       Date:  1994-04-28       Impact factor: 91.245

10.  Study of the effect of concomitant food on the bioavailability of rifampicin, isoniazid and pyrazinamide.

Authors:  C Zent; P Smith
Journal:  Tuber Lung Dis       Date:  1995-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.